Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric phase 3 study of rFIXFc for hemophilia B
2011-003076-36Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2011
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eftrenonacog alfa in hemophilia B (HB), sponsored by Biogen. Primary endpoint: Frequency of inhibitor development. Started Dec 2011; status: completed.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2011-003076-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003076-36.